New software has been developed that can reveal the detailed RNA-binding properties of proteins, which is important for characterising the pathology of many diseases.
List view / Grid view
Filter the results
Researchers have created an AI model that analyses the citations of studies, predicting their potential for eventual clinical application.
A new platform brings together genome editing with magnetic cell sorting to reveal new drug targets for cancer and regenerative medicine.
A new platform combines AI, flow chemistry and robotics to minimise the need for human intervention in the synthesis process.
Marc Baiget-Francesch highlights interesting developments in the field of protein drug design and explains how continual software improvements are speeding up the process.
There is still much to be done regarding how training is delivered and monitored in core technologies such as flow cytometry. Here, Derek Davies outlines the approaches his team at The Francis Crick Institute are taking to train users of such technologies to ensure quality data is obtained and best…
As research moves forward at a rapid pace and data is being generated in larger quantities than ever before, one problem the scientific community faces is reproducibility.
As technology advances and scientific research progresses at a rapid pace, data is being generated in ever-larger quantities. Even with the forward strides in technology and advances in data processing, a common problem widely acknowledged by the scientific community is that of reproducibility. In this article, Matjaz Hren discusses the…
Whitepaper: Evaluating the impact of error rate on productivity and cost savings in synthetic DNA fragments
GeneArt High-Q Strings DNA Fragments versus other suppliers’ products.
Innovations in synthesis technology and gene synthesis have become a powerful and valuable means of obtaining genetic material.
It is predicted that there will be 70 new monoclonal antibody (mAb) biotherapeutics available by 2020.
The number of oligonucleotide-based platforms on the market is constantly increasing and has led to the emergence of innovative nucleic acid-based therapeutic modalities such as CRISPR-Cas, sgRNAs or mRNAs.
New lab on a chip technology has been developed to evaluate the effects of different drivers of NAFLD on liver cells.